Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea. (Q51419447)

5 April 2018

title

Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea. (English)

1 reference

5 April 2018

14

Kyoung-Mee Kim

1 reference

5 April 2018

author name string

Taekyu Lim

1

1 reference

5 April 2018

Jeeyun Lee

2

1 reference

5 April 2018

Jae J Kim

3

1 reference

5 April 2018

Jong Kyun Lee

4

1 reference

5 April 2018

Kyu Taek Lee

5

1 reference

5 April 2018

Young Ho Kim

6

1 reference

5 April 2018

Kwang-Won Kim

7

1 reference

5 April 2018

Sung Kim

8

1 reference

5 April 2018

Tae Sung Sohn

9

1 reference

5 April 2018

Dong Wook Choi

10

1 reference

5 April 2018

Seong Ho Choi

11

1 reference

5 April 2018

Ho-Kyung Chun

12

1 reference

5 April 2018

Woo Young Lee

13

1 reference

5 April 2018

Kee-Taek Jang

15

1 reference

5 April 2018

Young Suk Park

16

1 reference

5 April 2018

publication date

1 September 2011

1 reference

5 April 2018

Asia Pacific Journal of Clinical Oncology

published in

1 reference

5 April 2018

volume

7

1 reference

5 April 2018

page(s)

293-299

1 reference

5 April 2018

issue

3

1 reference

5 April 2018

A 5-decade analysis of 13,715 carcinoid tumors

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Updated population-based review of carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Gastrointestinal carcinoids: characterization by site of origin and hormone production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Hepatic neuroendocrine metastases: does intervention alter outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

The diagnosis and medical management of advanced neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1743-7563.2011.01423.X

10.1111/J.1743-7563.2011.01423.X

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

PubMed ID

21884442

1 reference

5 April 2018